Piper Jaffray analyst Danielle Brill said she believes Alkermes "is making some positive changes" with its restructuring plans, adding that the company's need for pipeline growth was reinforced by "another disappointing revision" to its outlook for Aristada revenue. In Q3, Aristada's slower than anticipated growth was offset by higher than anticipated Sustenna royalties, helping the company to beat revenue expectations and maintain its FY19 guidance, Brill noted. She doubts that the company's Vumerity and 3831 opportunities will offset upcoming royalty expirations, leading her to keep a Neutral rating on the stock, but Brill added that she could get more constructive on Alkermes if it makes promising pipeline additions.